

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

September 30, 2014

Via E-mail
Jeffrey B. Davis
Chief Executive Officer
Access Pharmaceuticals, Inc.
4848 Lemmon Avenue, Suite 517
Dallas, Texas 75219

Re: Plasmatech Biopharmaceuticals, Inc. (f/k/a Access Pharmaceuticals, Inc.)

Preliminary Proxy Statement on Schedule 14C

Filed September 22, 2014

File No. 001-15771

Dear Mr. Davis:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler Assistant Director